drugset
drugset / Trial / NCT06830629

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629 ↗

Phase 2 Recruiting 56 enrolled Maze Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Timeline

Start
2025-02-05
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MZE829 Unknown — Oral

Indications

proteinuria